Clinical trial Recruiting at 3 sites Interventional Ages 16 and up

Rehabilitation program for spastic ataxias

Official title: IMPACT, a Supervised Rehabilitation Program for Spastic Ataxias: A Rater-blinded, Randomized Controlled Trial

Run by Laval University · NCT06261424 · Data updated 2026-11-12

This study is testing a 12-week rehabilitation program to see if it can help people with specific types of spastic ataxia feel better compared to regular care.

Quick facts

Study typeInterventional
Ages16 Years and up
SexAll
Enrollment84 (estimated)
SponsorLaval University
Academic / other
Locations5 sites (Baie-Saint-Paul, Quebec and 4 other locations)
StatusRecruiting
StartedFebruary 1, 2024
Main results expectedApril 2026
Study endsMarch 2027
Registry record updatedFebruary 18, 2026
Trial IDNCT06261424 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals with a confirmed genetic diagnosis of ARSACS or SPG7 who can maintain a standing position and provide informed consent.

Probably not a fit

Patients with other conditions causing physical limitations or those uncomfortable in a swimming pool may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effects of a 12-week supervised rehabilitation program on individuals with Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay and Spastic Paraplegia 7. The program aims to improve disease severity compared to usual care, identify factors influencing its implementation in clinical settings, and explore the cost-benefits of the rehabilitation approach. Participants will engage in targeted exercises designed to address their specific symptoms, with the program having been previously pilot-tested for effectiveness.

Why it matters

Potential benefit: If successful, this program could significantly improve mobility and quality of life for patients suffering from spastic ataxias.

How similar studies have gone: While there is limited research specifically targeting spastic ataxias, similar rehabilitation programs for other neurological conditions have shown promising results.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* have a confirmed genetic diagnosis of ARSACS or SPG7
* be able to maintain standing position and to transfert
* be authorized by their treating neurologist
* speak French or English
* be able to give informed consent.

Exclusion Criteria:

* have active participation in a rehabilitation program (self-reported information)
* have another condition causing physical limitations
* be uncomfortable in a swimming pool
* be pregnant.

Where it's running

  • CIUSSS du Centre-Sud-de-l'Île-de-Montréal, installation Centre de réadaptation Lucie-Bruneau
    Montreal, Quebec, Canada
    Recruiting
  • CIUSSS de la Capitale-Nationale, installation IRDPQ
    Québec, Quebec, Canada
    Recruiting
  • Clinique des maladies neuromusculaires du Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Saguenay-Lac-Saint-Jean, installation Hôpital Jonquière
    Saguenay, Quebec, Canada
    Recruiting
  • CIUSSS de la Capitale-Nationale, Hôpital de Baie-Saint-Paul
    Baie-Saint-Paul, Quebec, Canada
    Not yet recruiting
  • CIUSSS de la Capitale-Nationale, Hôpital de La Malbaie
    La Malbaie, Quebec, Canada
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.